Study says companies spend $100 million to promote blockbuster drugs

A study by Cutting Edge Information, Driving Successful Pharma Brands: Case Studies of Real Product Launches, said companies promoting blockbuster products routinely spend over $100 million on commercialization from Phase 3 through the first year that the product is publicly available. The study said Lilly will need an aggressive campaign for Prasugrel to compete with Bristol-Myers Squibb/Sanofi-Aventis's Plavix in Europe, where the delayed-in-the-US Lilly drug won approval. 
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.